arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 9/2013 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    DPP-4 inhibitors - clinical benefit still unproven

    NEW ON THE MARKET

    Lisdexamfetamine (ELVANSE) as second-line therapy for treatment-refractory attention deficit hyperactivity disorder?

    THERAPY FROM A CRITICAL VIEWPOINT

    Vaccination against rotavirus for all infants?

    a-t READERS' QUESTIONS AND COMMENTS

    Which contraceptive to use after venous thromboembolism?

    Opioid substitution: is levomethadone (L-POLAMIDON) safer than methadone (e.g. METHADDICT)?

    IN BRIEF

    Enough: 30 years of flunitrazepam (ROHYPNOL, generics)

    CURRENT ADR NETWORK REPORT

    Angioedema with ALMASED powder

    SIDE EFFECTS

    Progressive multifocal leukoencephalopathy (PML) with fingolimod (GILENYA) Promotion of quinine (LIMPTAR N) against leg cramps New warnings and contraindications for mefloquine

    e a-t IN INTERNET

    Anaphylactic reactions with chlorhexidine (e.g. CHLORHEXAMED)
    free

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles